FDMT
4D Molecular TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive readouts and/or a major partnership would validate the capsid platform, accelerate licensing/revenue potential and prompt multiple expansion.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +6.5.
What can break
Negative trial results, manufacturing or regulatory setbacks, or dilutive financings would materially compress valuation for this small‑cap biotech.
Momentum
44
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.98 · Bull $2.97 · Bear $0.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-24 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $35.33
Why
Momentum44 · Δ7d +6.5
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
44
34% active weight
Current posture
7d trendImproving
Δ7d
+6.5
Δ21d
-25.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 43.8 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$484.6M
Beta
3.00
Shares Out
57.14M
P/E (TTM) · Derived
-2.8
P/S (TTM)
3475.72
P/FCF (TTM) · Derived
-2.56
Rev YoY
+2900.0%
EPS YoY
-28.4%
Gross Margin
-
Op Margin
-191982.5%
Net Debt
-$424.88M
Current Ratio
8.42
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology